News >

Weighing Treatment Strategies in ALK+ NSCLC

Caroline Seymour
Published: Monday, Jul 15, 2019

Alice T. Shaw, MD, PhD

Alice T. Shaw, MD, PhD
The global phase III ALEX trial presented some of the most compelling data the field of ALK-positive non–small cell lung cancer (NSCLC) has ever seen, enabling a second-generation TKI to be pursued in the frontline setting, said Alice T. Shaw, MD, PhD. These data also opened the door for a more active investigation of sequencing and combination strategies that are contingent upon anticipated resistance mechanisms.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication